A. Mice were implanted with CT-2A mouse glioma cells (1 x 10 4 ) on day 0, and treated with PBS (upper) or rat anti-(a)PD-L1 antibody (lower; 500 µg/mouse) injected intraperitoneally (IP) on day 20, and sacrificed 2.5 hr later.
aPD-L1 was detected in the tumor with HRP-conjugated anti-(a)rat Ig (brown). HRP-conjugated anti-(a)rabbit Ig served as a control. Representative images as noted, scale bar = 100 µm. * normal brain adjacent to tumor. Figure 3C experiment. Mice were sacrificed on the following days: 41 for Mock; 61 for aCTLA-4; 48 for G47∆-mIL12; 78 for aCTLA-4 + G47∆-mIL12; and 133 for cured aCTLA-4 + G47∆-mIL12. B. 005 GSCs (1.5 x 10 5 ) were implanted on day 0, treated with PBS or G47Δ-mIL12 (5 x 10 5 pfu) injected IT on day 11 and IgG or aCTLA-4 antibody (5 mg/kg) injected IP on days 11, 14, and 17 (n=4/group), and mice were sacrificed on day 18 (same experiment as in Figure 3E ). Tumors harvested, cells stained with fluorochrome- A. C57Bl/6 mice were implanted with 005 GSCs (5 x 10 5 ) on day 0. G47∆-mIL12 (1 x 10 6 pfu/mouse) or PBS was injected IT and aCTLA-4 and aPD-1 or isotype control IgG (5 mg/kg hamster IgG and 10 mg/kg rat IgG)
B. Brain sections from 005 mice in
injected IP on day 19 (n=2/group). 36 hr after virus/antibodies injections, mice were perfused with ice-cold PBS, followed by brain fixative. Brains were stained for X-gal, frozen, sectioned and further stained for X-gal and counterstained with hematoxylin. X-gal stains virus-infected cells due to LacZ expression. Images from G47∆-mIL12 with control IgG (left) or CPi (aCTLA-4 and aPD-1 antibodies; right), with scale bar = 200 µm. * normal brain. Figure 4A , illustrating the lack of toxicity from therapy, except for day 11 in triple combination treatment group (V+CPi), after virus injection. Mock, PBS+IgG; CPi, aCTLA-4 and aPD-1 antibodies; CPi+V, G47∆-mIL12+aCTLA-4 and aPD-1 antibodies. Data presented as mean ± SEM.
B. Mean body weight measurements for mice depicted in
C. Brain sections from 005 mice in the re-challenge experiment in Figure 4B . Cured mice that were re-challenged (right) had needle track wounds on both sides of the brain (sacrificed day 96 after re-challenge). Control (left), naive mouse succumbed to tumor (day 42).
D.
Brain sections from CT-2A mice in the re-challenge experiment in Figure 4D . Cured mice that were rechallenged (right) had needle track wounds on both sides of the brain (sacrificed day 46 after re-challenge).
Control (left), naive mouse succumbed to tumor (day 12). A. Same sections as in Figure 6A were stained for cleaved caspase 3 (apoptosis), Granzyme B (cytolysis), FoxP3 
